|
Eine Ebene nach oben |
Gruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 22
2021
Müller, V.; Banys-Paluchowski, M.; Friedl, T. W. P.; Fasching, P. A.; Schneeweiss, A.; Hartkopf, A.; Wallwiener, D.; Rack, B.; Meier-Stiegen, F.; Huober, J.; Rübner, M.; Hoffmann, O.; Müller, L.; Janni, W.; Wimberger, P.; Jäger, B.; Pantel, K.; Riethdorf, S.; Harbeck, N. und Fehm, T.
(2021):
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program.
In: Esmo Open, Bd. 6, Nr. 6
2020
Hack, C. C.; Haeberle, L.; Brucker, S. Y.; Janni, W.; Volz, B.; Loehberg, C. R.; Hartkopf, A. D.; Walter, C.-B.; Baake, G.; Fridman, A.; Malter, W.; Würstlein, R.; Harbeck, N.; Hoffmann, O.; Kuemmel, S.; Martin, B.; Thomssen, C.; Graf, H.; Wolf, C.; Lux, M. P.; Bayer, C. M.; Rauh, C.; Almstedt, K.; Gass, P.; Heindl, F.; Brodkorb, T.; Willer, L.; Lindner, C.; Kolberg, H-C; Krabisch, P.; Weigel, M.; Steinfeld-Birg, D.; Kohls, A.; Brucker, C.; Schulz, V.; Fischer, G.; Pelzer, V.; Rack, B.; Beckmann, M. W.; Fehm, T.; Rody, A.; Maass, N.; Hein, A.; Fasching, P. A. und Nabieva, N.
(2020):
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients.
In: Breast, Bd. 50: S. 11-18
2018
Nabieva, N.; Fehm, T.; Haeberle, L.; Waal, J. de; Rezai, M.; Baier, B.; Baake, G.; Kolberg, H. -C.; Guggenberger, M.; Warm, M.; Harbeck, N.; Würstlein, R.; Deuker, J. -U.; Dall, P.; Richter, B.; Wachsmann, G.; Brucker, C.; Siebers, J. W.; Popovic, M.; Kuhn, T.; Wolf, C.; Vollert, H. -W.; Breitbach, G. -P.; Janni, W.; Landthaler, R.; Kohls, A.; Rezek, D.; Noesselt, T.; Fischer, G.; Henschen, S.; Praetz, T.; Heyl, V.; Kuehn, T.; Krauss, T.; Thomssen, C.; Hohn, A.; Tesch, H.; Mundhenke, C.; Hein, A.; Hack, C. C.; Schmidt, K.; Belleville, E.; Brucker, S. Y.; Kuemmel, S.; Beckmann, M. W.; Wallwiener, D.; Hadji, P. und Fasching, P. A.
(2018):
Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.
In: European Journal of Cancer, Bd. 96: S. 82-90
Witzel, I.; Laakmann, E.; Weide, R.; Neunhoeffer, T.; Park-Simon, T. -J.; Schmidt, M.; Fasching, P. A.; Hesse, T.; Polasik, A.; Mohrmann, S.; Wuerschmidt, F.; Schem, C.; Bechtner, C.; Würstlein, R.; Fehm, T.; Moebus, V.; Burchardi, N.; Loibl, S. und Müller, V.
(2018):
Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry.
In: European Journal of Cancer, Bd. 102: S. 1-9
Nabieva, N.; Kellner, S.; Fehm, T.; Häbrle, L.; Waal, J. de; Rezai, M.; Baier, B.; Baake, G.; Kolberg, H.-C.; Guggenberger, M.; Warm, M.; Harbeck, N.; Würstlein, R.; Deuker, J.-U.; Dall, P.; Richter, B.; Wachsmann, G.; Brucker, C.; Siebers, J. W.; Fersis, N.; Kuhn, T.; Wolf, C.; Vollert, H.-W.; Breitbach, G.-P.; Janni, W.; Landthaler, R.; Kohls, A.; Rezek, D.; Nösselt, T.; Fischer, G.; Henschen, S.; Prätz, T.; Heyl, V.; Kühn, T.; Krauss, T.; Thomssen, C.; Hohn, A.; esch, H.; Mundhenke, C.; Hein, A.; Rauh, C.; Bayer, C. M.; Jacob, A.; Schmidt, K.; Belleville, E.; Brucker, S. Y.; Kümmel, S.; Beckmann, M. W.; Wallwiener, D.; Hadji, P. und Fasching, P. A.
(2018):
Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients.
In: Annals of Oncology, Bd. 29, Nr. 1: S. 186-192
2017
Krajnak, S.; Decker, T.; Fehm, T.; Fuxius, S.; Harbeck, N.; Juhasz-Böss, I.; Möbus, V.; Thomssen, C.; Seehase, M.; Schollenberger, L.; Ruckes, C. und Schmidt, M.
(2017):
VinoMetro: phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2-breast cancer resistant to endocrine therapy.
In: Oncology Research and Treatment, Bd. 40: S. 88
Tzschaschel, M. L. J.; Rack, B.; Majunke, L.; Trapp, E. K.; Mahner, S.; Fasching, P. A.; Fehm, T.; Schneeweiss, A.; Friedl, T. W. P.; Polasik, A.; Janni, W. und Alunni-Fabbroni, M.
(2017):
Profiling miRNA in high risk postoperative early breast cancer patients to detect possible association to correlation with immune system antitumor response.
In: Cancer Research, Bd. 77
Polasik, A.; Schramm, A.; Friedl, T. W. P.; Rack, B.; Trapp, E.; Tzschaschel, M.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pantel, K.; Meier-Stiegen, F.; Wimberger, P.; Janni, W. und Fehm, T.
(2017):
The DETECT V-study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo-or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer.
In: Cancer Research, Bd. 77
Polasik, A.; Schramm, A.; Friedl, T. W. P.; Rack, B.; Trapp, E.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pantel, K.; Meier-Stiegen, F.; Wimberger, P.; Janni, W. und Fehm, T.
(2017):
DETECT III and IV - Individualized CTC-based therapy of metastatic breast cancer.
In: Cancer Research, Bd. 77
Janni, W.; Rack, B.; Häberle, L.; Friedl, T. W. P.; Tesch, H.; Lorenz, R.; Jäger, B.; Fehm, T.; Müller, V.; Schneeweiß, A.; Lichtenegger, W.; Blohmer, J.; Beckmann, M. W.; Scholz, C.; Pantel, K.; Trapp, E. und Fasching, P. A.
(2017):
Active surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells two year after primary diagnosis strongly predicts subsequent prognosis.
In: Cancer Research, Bd. 77
Fehm, T.; Meier-Stiegen, F.; Riethdorf, S.; Schramm, A.; Polasik, A.; Niederacher, D.; Rack, B.; Taran, F.-A.; Müller, V.; Janni, W. und Huober, J.
(2017):
DETECT V - Detection of the expression of estrogen receptor and human epidermal growth factor receptor 2 on circulating tumor cells from metastatic breast cancer patients.
In: Cancer Research, Bd. 77
Elger, T.; Decker, T.; Fehm, T.; Fuxius, S.; Harbeck, N.; Juhasz-Böss, I.; Möbus, V.; Thomssen, C.; Seehase, M.; Schollenberger, L.; Ruckes, C. und Schmidt, M.
(2017):
VinoMetro: Phase II study of metronomic daily oral vinorelbine as first-line chemotherapy in advanced/metastatic hormone receptor positive (HR plus )/human epidermal growth factor receptor 2 negative (HER2-) breast cancer resistant to endocrine therapy.
In: Annals of Oncology, Bd. 28
Hein, A.; Rack, B.; Li, L.; Ekici, A. B.; Reis, A.; Lux, M. P.; Cunningham, J. M.; Rübner, M.; Fridley, B. L.; Schneeweiss, A.; Tesch, H.; Lichtenegger, W.; Fehm, T.; Heinrich, G.; Rezai, M.; Beckmann, M. W.; Janni, W.; Weinshilboum, R. M.; Wang, L.; Fasching, P. A. und Häberle, L.
(2017):
Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study.
In: Geburtshilfe und Frauenheilkunde, Bd. 77, Nr. 6: S. 651-659
Jäger, B. A. S.; Neugebauer, J.; Andergassen, U.; Melcher, C.; Schochter, F.; Mouarrawy, D.; Ziemendorff, G.; Clemens, M.; Abel, E. v.; Heinrich, G.; Schüller, K.; Schneeweiss, A.; Fasching, P.; Beckmann, M. W.; Scholz, Ch.; Friedl, T. W. P.; Friese, K.; Pantel, K.; Fehm, T.; Janni, W. und Rack, B.
(2017):
The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial.
In: PLOS One 12(6), e0173593 [PDF, 1MB]
In: PLOS One 12(6), e0173593 [PDF, 1MB]
2016
Schramm, A.; Fried, T. W. P.; Huober, J.; Jäger, B.; Rack, B.; Trapp, E.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pante, K.; Meier-Stiegen, F.; Wimberger, P.; Kümmel, S.; Gebauer, G.; Müller, L.; Janni, W. und Fehm, T.
(2016):
The DETECT study program - Personalized treatment in metastatic breast cancer based on circulating tumor cells.
In: Cancer Research, Bd. 76
Janning, M.; Müller, V; Vettorazzi, E.; Cubas-Cordova, M.; Gensch, V; Ben Batalla, I; Eulenburg, C. zu; Schem, C.; Fasching, P. A.; Schnappauf, B.; Karn, T.; Fehm, T.; Just, M.; Kühn, T.; Holms, F.; Overkamp, F.; Krabisch, P.; Rack, B.; Denkert, C.; Untch, M.; Tesch, H.; Rezai, M.; Kittel, K.; Pantel, K.; Bokemeyer, C.; Loibl, S.; Minckwitz, G. von und Loges, S.
(2016):
Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial.
In: Oncology Research and Treatment, Bd. 39: S. 185
Janni, W.; Rack, B.; Fasching, P.; Haeberle, L.; Friedl, T.; Tesch, H.; Lorenz, R.; Neugebauer, J.; Koch, J.; Jaeger, B.; Fehm, T.; Mueller, V.; Schneeweiß, A.; Lichtenegger, W.; Beckmann, M.; Scholz, C.; Pantel, K. und Trapp, E.
(2016):
Persistence of circulating tumor cells in high risk early breast cancer patients during follow-up care suggests poor prognosis - Results from the adjuvant SUCCESS A trial.
In: Cancer Research, Bd. 76
Tzschaschel, M.; Trapp, E.; Rack, B.; Messina, C.; Mueller, V.; Fehm, T.; Janni, W.; Loehberg, C.; Wimberger, P.; Kolberg, H.-C.; Uleer, C.; Brudler, O.; Sotiriou, C.; Pierga, J.-Y.; Piccart, M. und Ignatiadis, M.
(2016):
TREAT CTC: An innovative therapy approach to eliminate circulating tumor cells (CTCs).
In: Oncology Research and Treatment, Bd. 39: S. 55
Janni, W.; Schramm, A.; Friedl, T. W. P.; Schochter, E.; Huober, J.; Rack, B.; Alunni-Fabbroni, M.; Fasching, P. A.; Taran, F.-A.; Hortkopf, A.; Schneeweiss, A.; Mueller, V.; Aktas, B.; Krawczyk, N.; Pantel, K. und Fehm, T.
(2016):
Factors Predicting Discordance in HER2 Phenotype between Primary Tumor and Circulating Tumor Cells in Women with Metastatic Breast Cancer.
In: Oncology Research and Treatment, Bd. 39: S. 47
Schramm, A.; Friedl, T.; Rack, B.; Trapp, E.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pantel, K.; Meier-Stiegen, F.; Wimberger, P.; Kümmel, S.; Gebauer, G.; Müller, L.; Janni, W. und Fehm, T.
(2016):
The DETECT Study Concept - Metastatic breast cancer and circulating tumor cells.
In: Oncology Research and Treatment, Bd. 39: S. 46-47
Fehm, T.; Schultz, S.; Bartsch, H.; Petat-Dutter, K.; Kahlert, S.; Sotlar, K.; Niederacher, D. und Neubauer, H.
(2016):
Verification of the breast cancer progression-associated miRNA hsa-miR-199a-5p using NanoString (R) platform.
In: Cancer Research, Bd. 76
Janni, W.; Schramm, A.; Friedl, T. W. P.; Schochter, F.; Huober, J.; Rack, B.; Alunni-Fabbroni, M.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Krawczyk, N.; Pantel, K. und Fehm, T.
(2016):
Predictors for discordance in HER2 phenotype between primary tumor and circulating tumor cells in women with metastatic breast cancer.
In: Cancer Research, Bd. 76